BRIDGEWATER, N.J. – Bausch + Lomb, the leading global eye health company, today announced the introduction of PureVision®2 Multi-Focal (balafilcon A) visibility tinted contact lenses for presbyopia, a monthly silicone hydrogel multifocal contact lens packaged in borate buffered saline. Featuring a next generation 3-Zone Progressive™ design, these innovative lenses are designed to improve near and intermediate vision while providing excellent distance clarity1. The new PureVision2 for presbyopia lenses provide clarity where it counts—in the real world.
“The innovation behind PureVision2 for presbyopia demonstrates Bausch + Lomb’s commitment to helping people see better to live better. We know that consistent, crisp, clear vision at all distances can be a challenge for people with presbyopia. These new lenses will provide that consistency whether viewing a screen on your mobile phone or a screen at the cinema,” said Joseph Barr, OD, MS, vice president, Medical Affairs, Pharmaceuticals, Vision Care, Bausch + Lomb. “We’re optimistic that the combination of a streamlined fit and a satisfied patient will make this lens a favorite for the eye care professional.”
The innovative lens design allows for a predictable2, quick fit for the eye care professional. In a recent survey, more than 95 percent of eye care professionals agreed that PureVision2 for presbyopia lenses helped maintain clear near, intermediate, and distance vision in real world conditions. Ninety percent of eye care professionals agree that PureVision2 for presbyopia lenses are easier to fit than other multifocal contact lenses.2
“PureVision2 for presbyopia allows me to fit my patients more effectively and efficiently which has streamlined what can be a time consuming process,” said Dr. Michael DePaolis, OD, FAAO. “With the PureVision2 for presbyopia lenses I’m able to provide my patients with exceptional clarity throughout the day at various distances.”
PureVision2 for presbyopia contact lenses are available for extended wear up to 30 days* and are the latest multifocal innovation to be added to Bausch + Lomb’s PureVision®2 line of contact lenses. Featuring multifocal lens technology licensed from Unilens Vision, Inc., the lens is designed to deliver the clear, crisp vision patients demand. These lenses are now available in the U.S. in a full range of parameters, and will be introduced in other markets throughout 2013.
About Bausch + Lomb
Bausch + Lomb, a Valeant Pharmaceuticals International, Inc. company, is a leading global eye health organization that is solely focused on protecting, enhancing, and restoring people’s eyesight. Our core businesses include ophthalmic pharmaceuticals, contact lenses and lens care products, and ophthalmic surgical devices and instruments. We globally develop, manufacture and market one of the most comprehensive product portfolios in our industry, which are available in more than 100 countries.
®/™ are trademarks of Bausch & Lomb Incorporated or its affiliates.
HL-6631
News Media Contacts:
Kristy Guerra
U.S. Public Relations Product Manager, Bausch + Lomb
585-338-8095 or kristy.guerra@bausch.com
Don Murphy
Zeno Group on behalf of Bausch + Lomb
212-299-8970 or don.murphy@zenogroup.com
1 Analysis based on use of Hartmann-Shack wavefront sensing instruments applying high lateral resolution to map lens power across a contact lens. More than 6000 unique measurements over the central 6mm of a contact lens were plotted to determine local power measurement as a function of radial distance from the center of the lens.
2 Thirty-nine ECPs (from 10 countries) refitted 422 existing soft contact lens wearing presbyopes into PureVision2 for Presbyopia. Patients returned for follow-up visits after 1-2 weeks. ECP assessment of lens performance including ease of fit, and patient satisfaction with lenses in real world conditions, were measured using a 6-point agreement survey.
*Brief summary of intended use: The Bausch + Lomb PureVision®2 Multi-Focal (balafilcon A) Visibility Tinted Contact Lenses are indicated for daily or extended wear for up to 30 nights between removals.
Warnings: The risk of microbial keratitis has been shown to be greater among users of extended wear contact lenses than among users of daily wear contact lenses. The long-term risk of microbial keratitis has not been determined for this lens. Post-marketing studies are in progress.
Precautions: Some patients will not be able to tolerate continuous wear even if able to tolerate the same or another lens on a daily wear basis. Some patients who are able to tolerate continuous wear will not be able to wear their lenses continuously for 30 nights. Patients should be carefully evaluated for continuous wear prior to prescription and dispensing, and eye care professionals should conduct early and frequent follow-up examination to determine ocular response to continuous wear.
Side effects: During the one-year US study, 2.9% of the 820 eyes that were fit with the PureVision* lens in one eye experienced infiltrative keratitis. Other less serious side effects were mild forms of dryness, discomfort, and burning and stinging.
Contraindications: The lens should not be used in the presence of any inflammation, infection, disease or injury in or around the eye or eyelids that interferes with contact lens wear. The lenses should not be used by individuals who have a systemic disease or an allergic condition that might interfere with contact lens wear.
Consult the Package Insert/Fitting Guide for complete information about PureVision2 contact lenses, available from Bausch + Lomb at 1-800-553-5340 or www.bausch.com.
* Based on a study conducted with BAUSCH & LOMB PureVision (balafilcon A) Visibility Tinted Contact Lens.
United States
